178 related articles for article (PubMed ID: 28981092)
1. Executioner caspases and CAD are essential for mutagenesis induced by TRAIL or vincristine.
Miles MA; Hawkins CJ
Cell Death Dis; 2017 Oct; 8(10):e3062. PubMed ID: 28981092
[TBL] [Abstract][Full Text] [Related]
2. TRAIL treatment provokes mutations in surviving cells.
Lovric MM; Hawkins CJ
Oncogene; 2010 Sep; 29(36):5048-60. PubMed ID: 20639907
[TBL] [Abstract][Full Text] [Related]
3. Proteasome inhibitors trigger mutations via activation of caspases and CAD, but mutagenesis provoked by the HDAC inhibitors vorinostat and romidepsin is caspase/CAD-independent.
Miles MA; Harris MA; Hawkins CJ
Apoptosis; 2019 Jun; 24(5-6):404-413. PubMed ID: 30997620
[TBL] [Abstract][Full Text] [Related]
4. In vitro analysis reveals necroptotic signaling does not provoke DNA damage or HPRT mutations.
Miles MA; Hawkins CJ
Cell Death Dis; 2020 Aug; 11(8):680. PubMed ID: 32826875
[TBL] [Abstract][Full Text] [Related]
5. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin.
Zhang XD; Wu JJ; Gillespie S; Borrow J; Hersey P
Clin Cancer Res; 2006 Feb; 12(4):1355-64. PubMed ID: 16489094
[TBL] [Abstract][Full Text] [Related]
6. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
Singh TR; Shankar S; Chen X; Asim M; Srivastava RK
Cancer Res; 2003 Sep; 63(17):5390-400. PubMed ID: 14500373
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent increase of the pro- to anti-apoptotic proteins ratio.
Mühlethaler-Mottet A; Flahaut M; Bourloud KB; Auderset K; Meier R; Joseph JM; Gross N
BMC Cancer; 2006 Aug; 6():214. PubMed ID: 16930472
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin (CDDP) specifically induces apoptosis via sequential activation of caspase-8, -3 and -6 in osteosarcoma.
Seki K; Yoshikawa H; Shiiki K; Hamada Y; Akamatsu N; Tasaka K
Cancer Chemother Pharmacol; 2000; 45(3):199-206. PubMed ID: 10663637
[TBL] [Abstract][Full Text] [Related]
9. C-jun N-terminal kinase activation is required for apoptotic cell death induced by TNF-related apoptosis-inducing ligand plus DNA-damaging agents in sarcoma cell lines.
Mikami T; Koyama T; Koyama T; Imakiire A; Yamamoto K; Furuhata M; Toyota H; Mizuguchi J
Anticancer Res; 2006; 26(2A):1153-60. PubMed ID: 16619517
[TBL] [Abstract][Full Text] [Related]
10. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11.
Ray S; Almasan A
Cancer Res; 2003 Aug; 63(15):4713-23. PubMed ID: 12907654
[TBL] [Abstract][Full Text] [Related]
11. carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase (cad) regulates Notch signaling and vascular development in zebrafish.
Coxam B; Neyt C; Grassini DR; Le Guen L; Smith KA; Schulte-Merker S; Hogan BM
Dev Dyn; 2015 Jan; 244(1):1-9. PubMed ID: 25294789
[TBL] [Abstract][Full Text] [Related]
12. Mutagenic assessment of chemotherapy and Smac mimetic drugs in cells with defective DNA damage response pathways.
Miles MA; Hawkins CJ
Sci Rep; 2018 Sep; 8(1):14421. PubMed ID: 30258062
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapeutic agents sensitize sarcoma cell lines to tumor necrosis factor-related apoptosis-inducing ligand-induced caspase-8 activation, apoptosis and loss of mitochondrial membrane potential.
Hotta T; Suzuki H; Nagai S; Yamamoto K; Imakiire A; Takada E; Itoh M; Mizuguchi J
J Orthop Res; 2003 Sep; 21(5):949-57. PubMed ID: 12919886
[TBL] [Abstract][Full Text] [Related]
14. Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis.
Lacour S; Hammann A; Wotawa A; Corcos L; Solary E; Dimanche-Boitrel MT
Cancer Res; 2001 Feb; 61(4):1645-51. PubMed ID: 11245478
[TBL] [Abstract][Full Text] [Related]
15. Biallelic mutations in CAD, impair de novo pyrimidine biosynthesis and decrease glycosylation precursors.
Ng BG; Wolfe LA; Ichikawa M; Markello T; He M; Tifft CJ; Gahl WA; Freeze HH
Hum Mol Genet; 2015 Jun; 24(11):3050-7. PubMed ID: 25678555
[TBL] [Abstract][Full Text] [Related]
16. Role of caspases in CD95L- and TRAIL-induced non-apoptotic signalling in pancreatic tumour cells.
Siegmund D; Klose S; Zhou D; Baumann B; Röder C; Kalthoff H; Wajant H; Trauzold A
Cell Signal; 2007 Jun; 19(6):1172-84. PubMed ID: 17291719
[TBL] [Abstract][Full Text] [Related]
17. Triacetyluridine treats epileptic encephalopathy from CAD mutations: a case report and review.
Frederick A; Sherer K; Nguyen L; Ali S; Garg A; Haas R; Sahagian M; Bui J
Ann Clin Transl Neurol; 2021 Jan; 8(1):284-287. PubMed ID: 33249780
[TBL] [Abstract][Full Text] [Related]
18. Regulation of carbamoyl phosphate synthetase by MAP kinase.
Graves LM; Guy HI; Kozlowski P; Huang M; Lazarowski E; Pope RM; Collins MA; Dahlstrand EN; Earp HS; Evans DR
Nature; 2000 Jan; 403(6767):328-32. PubMed ID: 10659854
[TBL] [Abstract][Full Text] [Related]
19. Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy.
Wang S; El-Deiry WS
Proc Natl Acad Sci U S A; 2003 Dec; 100(25):15095-100. PubMed ID: 14645705
[TBL] [Abstract][Full Text] [Related]
20. Transcriptional repression of human cad gene by hypoxia inducible factor-1alpha.
Chen KF; Lai YY; Sun HS; Tsai SJ
Nucleic Acids Res; 2005; 33(16):5190-8. PubMed ID: 16155188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
